<p>分析师对 Teva Pharmaceutical Indus（纽约证券交易所代码：TEVA）在过去一个季度的评级从看涨到看跌不等，共有 11 位分析师提供了相关信息。</p>
<p>在下面的表格中，您将找到他们最近评级的总结，揭示了过去 30 天情绪的变化，并与前几个月进行了比较。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析师通过对 12 个月价格目标的评估提供了更深入的见解，显示出平均目标为 35.36 美元，最高预估为 40.00 美元，最低预估为 28.00 美元。这一上升趋势显而易见，目前的平均值较之前的 30.22 美元的平均价格目标增长了 17.01%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769713231_0_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="价格目标图表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769713231_0_0.png"/></p>
<h2>深入分析分析师评级：全面探索</h2>
<p>通过对最近分析师行动的深入分析，清晰描绘了 Teva Pharmaceutical Indus 在金融专家中的认知。下面的总结概述了关键分析师、他们最近的评估以及对评级和价格目标的调整。</p>
<table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Louise Chen</td>
<td>Scotiabank</td>
<td>上调</td>
<td>行业表现优于大盘</td>
<td>$40.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Les Sulewski</td>
<td>Truist Securities</td>
<td>上调</td>
<td>买入</td>
<td>$38.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>上调</td>
<td>买入</td>
<td>$40.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>上调</td>
<td>超配</td>
<td>$40.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Matt Dellatorre</td>
<td>Goldman Sachs</td>
<td>上调</td>
<td>买入</td>
<td>$35.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>上调</td>
<td>超配</td>
<td>$35.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>上调</td>
<td>买入</td>
<td>$32.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Barclays</td>
<td>宣布</td>
<td>超配</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Matt Dellatorre</td>
<td>Goldman Sachs</td>
<td>上调</td>
<td>买入</td>
<td>$31.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Scotiabank</td>
<td>宣布</td>
<td>行业表现优于大盘</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>上调</td>
<td>超配</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
</tbody>
</table>
<h3>关键见解：</h3>
<ul>
<li><strong>采取的行动：</strong> 分析师对市场条件和公司表现的变化作出反应，频繁更新他们的建议。无论是 ‘维持’，‘上调’ 还是 ‘下调’ 他们的立场，反映了他们对 Teva Pharmaceutical Indus 最近发展的反应。这些信息提供了分析师对公司当前状态的看法快照。</li>
<li><strong>评级：</strong> 深入评估，分析师赋予定性值，从 ‘表现优于大盘’ 到 ‘表现不及大盘’。这些评级传达了对 Teva Pharmaceutical Indus 相对于更广泛市场的表现预期。</li>
<li><strong>价格目标：</strong> 分析师预测价格目标的变动，提供 Teva Pharmaceutical Indus 未来价值的估计。检查当前和之前的目标提供了分析师不断变化的预期的见解。</li>
</ul>
<p>通过这些分析师评估与其他财务指标的结合，可以帮助全面理解 Teva Pharmaceutical Indus 的市场地位。保持信息灵通，并通过我们的评级表做出数据驱动的决策。</p>
<p>随时了解 Teva Pharmaceutical Indus 的分析师评级。</p>
<h2>发现 Teva Pharmaceutical Indus：更深入的了解</h2>
<p>Teva Pharmaceutical，总部位于以色列，是全球领先的仿制药制造商。Teva 的销售一半来自北美，并占美国仿制药处方总数的高个位数百分比。它在欧洲、日本、俄罗斯和以色列也有显著的市场份额。除了仿制药，Teva 在三个主要治疗领域拥有创新药物和生物类似药的产品组合：中枢神经系统（Copaxone、Ajovy 和 Austedo）；呼吸系统（Qvar 和 ProAir）；以及肿瘤学（Truxima、Herzuma 和 Bendeka/Treanda）。Teva 还销售活性药物成分，提供合同制造服务，并拥有 Anda，一家美国的仿制药和特种药物分销商。</p>
<h3>Teva Pharmaceutical Indus 的财务表现</h3>
<p><strong>市值分析：</strong> 反映出较小的规模，该公司的市值低于行业平均水平。这可能归因于增长预期或运营能力等因素。</p>
<p><strong>收入增长：</strong> Teva Pharmaceutical Indus 在 2025 年 9 月 30 日的表现显著，收入增长率达到 <strong>3.42%</strong>。这表明公司在收入方面有了显著的提升。与行业同行相比，该公司的增长率低于医疗保健行业的平均水平。</p>
<p><strong>净利润率：</strong> Teva Pharmaceutical Indus 的净利润率低于行业标准，表明在实现强劲盈利能力方面面临困难。净利润率为 <strong>9.67%</strong>，公司可能在有效控制成本方面遇到挑战。</p>
<p><strong>股本回报率（ROE）：</strong> Teva Pharmaceutical Indus 的 ROE 表现突出，超过行业平均水平。ROE 为 <strong>6.15%</strong>，表明公司有效利用股本并展现出强劲的财务表现。</p>
<p><strong>资产回报率（ROA）：</strong> 该公司的 ROA 低于行业基准，表明在有效利用资产方面可能存在困难。ROA 为 <strong>1.08%</strong>，公司可能需要解决从资产中产生令人满意的回报的挑战。</p>
<p><strong>债务管理：</strong> 梯瓦制药的债务与股本比率显著高于行业平均水平，达到 <strong>2.35</strong>。这表明其对借款资金的依赖程度较高，令人对财务杠杆产生担忧。</p>
<h2>理解分析师评级的相关性</h2>
<p>分析师是银行和金融系统中的专家，通常针对特定股票或特定行业进行报告。这些人研究公司的财务报表，参加电话会议和会议，并与相关内部人士交谈，以确定股票的分析师评级。通常，分析师每季度会对每只股票进行评级。</p>
<p>除了标准评估外，一些分析师还会对增长预期、收益和收入等指标进行预测，为投资者提供额外的指导。使用分析师评级的用户应注意，这些专业建议受到人类观点的影响，可能会存在变动。</p>
<p>本文由 Benzinga 的自动内容引擎生成，并经过编辑审核。</p>

<p>分析师对梯瓦制药（NYSE:TEVA）的评级显示出看涨和看跌情绪的混合，过去一个季度共有 11 位分析师提供了见解。12 个月的平均目标价格已上升至 35.36 美元，比之前的目标上涨了 17.01%。主要分析师提高了他们的评级和目标价格，表明市场预期积极。梯瓦作为一家领先的仿制药制造商，收入增长了 3.42%，但面临净利润率为 9.67% 和高达 2.35 的债务股本比率的挑战，显示出对借款资金的依赖。分析师评级对投资者评估市场情绪和公司表现至关重要</p>

<p>Analysts' ratings for Teva Pharmaceutical Indus (NYSE: TEVA) over the last quarter vary from bullish to bearish, as provided by 11 analysts.</p>
<div class="lb-trans"><p>分析师对 Teva Pharmaceutical Indus（纽约证券交易所代码：TEVA）在过去一个季度的评级从看涨到看跌不等，共有 11 位分析师提供了相关信息。</p>
</div><p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<div class="lb-trans"><p>在下面的表格中，您将找到他们最近评级的总结，揭示了过去 30 天情绪的变化，并与前几个月进行了比较。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看涨</strong></th>
<th align="right"><strong>稍微看涨</strong></th>
<th align="right"><strong>无所谓</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>总评级</strong></td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>过去 30 天</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 个月前</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 个月前</strong></td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 个月前</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $35.36, a high estimate of $40.00, and a low estimate of $28.00. This upward trend is evident, with the current average reflecting a 17.01% increase from the previous average price target of $30.22.</p>
<div class="lb-trans"><p>分析师通过对 12 个月价格目标的评估提供了更深入的见解，显示出平均目标为 35.36 美元，最高预估为 40.00 美元，最低预估为 28.00 美元。这一上升趋势显而易见，目前的平均值较之前的 30.22 美元的平均价格目标增长了 17.01%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1769713231_0_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1769713231_0_0.png"/></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<div class="lb-trans"><h2>深入分析分析师评级：全面探索</h2>
</div><p>A clear picture of Teva Pharmaceutical Indus's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通过对最近分析师行动的深入分析，清晰描绘了 Teva Pharmaceutical Indus 在金融专家中的认知。下面的总结概述了关键分析师、他们最近的评估以及对评级和价格目标的调整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Louise Chen</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$40.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Les Sulewski</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$38.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$40.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Matt Dellatorre</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$35.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$32.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Matt Dellatorre</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$31.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析师</th>
<th>分析师公司</th>
<th>采取的行动</th>
<th>评级</th>
<th>当前价格目标</th>
<th>之前价格目标</th>
</tr>
</thead>
<tbody>
<tr>
<td>Louise Chen</td>
<td>Scotiabank</td>
<td>上调</td>
<td>行业表现优于大盘</td>
<td>$40.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Les Sulewski</td>
<td>Truist Securities</td>
<td>上调</td>
<td>买入</td>
<td>$38.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>上调</td>
<td>买入</td>
<td>$40.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>上调</td>
<td>超配</td>
<td>$40.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Matt Dellatorre</td>
<td>Goldman Sachs</td>
<td>上调</td>
<td>买入</td>
<td>$35.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>上调</td>
<td>超配</td>
<td>$35.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>上调</td>
<td>买入</td>
<td>$32.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Barclays</td>
<td>宣布</td>
<td>超配</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Matt Dellatorre</td>
<td>Goldman Sachs</td>
<td>上调</td>
<td>买入</td>
<td>$31.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Scotiabank</td>
<td>宣布</td>
<td>行业表现优于大盘</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>上调</td>
<td>超配</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>关键见解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Teva Pharmaceutical Indus. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Teva Pharmaceutical Indus compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Teva Pharmaceutical Indus's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>采取的行动：</strong> 分析师对市场条件和公司表现的变化作出反应，频繁更新他们的建议。无论是 ‘维持’，‘上调’ 还是 ‘下调’ 他们的立场，反映了他们对 Teva Pharmaceutical Indus 最近发展的反应。这些信息提供了分析师对公司当前状态的看法快照。</li>
<li><strong>评级：</strong> 深入评估，分析师赋予定性值，从 ‘表现优于大盘’ 到 ‘表现不及大盘’。这些评级传达了对 Teva Pharmaceutical Indus 相对于更广泛市场的表现预期。</li>
<li><strong>价格目标：</strong> 分析师预测价格目标的变动，提供 Teva Pharmaceutical Indus 未来价值的估计。检查当前和之前的目标提供了分析师不断变化的预期的见解。</li>
</ul>
</div><p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Teva Pharmaceutical Indus's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<div class="lb-trans"><p>通过这些分析师评估与其他财务指标的结合，可以帮助全面理解 Teva Pharmaceutical Indus 的市场地位。保持信息灵通，并通过我们的评级表做出数据驱动的决策。</p>
</div><p>Stay up to date on Teva Pharmaceutical Indus analyst ratings.</p>
<div class="lb-trans"><p>随时了解 Teva Pharmaceutical Indus 的分析师评级。</p>
</div><h2>Discovering Teva Pharmaceutical Indus: A Closer Look</h2>
<div class="lb-trans"><h2>发现 Teva Pharmaceutical Indus：更深入的了解</h2>
</div><p>Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.</p>
<div class="lb-trans"><p>Teva Pharmaceutical，总部位于以色列，是全球领先的仿制药制造商。Teva 的销售一半来自北美，并占美国仿制药处方总数的高个位数百分比。它在欧洲、日本、俄罗斯和以色列也有显著的市场份额。除了仿制药，Teva 在三个主要治疗领域拥有创新药物和生物类似药的产品组合：中枢神经系统（Copaxone、Ajovy 和 Austedo）；呼吸系统（Qvar 和 ProAir）；以及肿瘤学（Truxima、Herzuma 和 Bendeka/Treanda）。Teva 还销售活性药物成分，提供合同制造服务，并拥有 Anda，一家美国的仿制药和特种药物分销商。</p>
</div><h3>Teva Pharmaceutical Indus's Financial Performance</h3>
<div class="lb-trans"><h3>Teva Pharmaceutical Indus 的财务表现</h3>
</div><p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 反映出较小的规模，该公司的市值低于行业平均水平。这可能归因于增长预期或运营能力等因素。</p>
</div><p><strong>Revenue Growth:</strong> Teva Pharmaceutical Indus's remarkable performance in 3M is evident. As of 30 September, 2025, the company achieved an impressive revenue growth rate of <strong>3.42%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<div class="lb-trans"><p><strong>收入增长：</strong> Teva Pharmaceutical Indus 在 2025 年 9 月 30 日的表现显著，收入增长率达到 <strong>3.42%</strong>。这表明公司在收入方面有了显著的提升。与行业同行相比，该公司的增长率低于医疗保健行业的平均水平。</p>
</div><p><strong>Net Margin:</strong> Teva Pharmaceutical Indus's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>9.67%,</strong> the company may encounter challenges in effective cost control.</p>
<div class="lb-trans"><p><strong>净利润率：</strong> Teva Pharmaceutical Indus 的净利润率低于行业标准，表明在实现强劲盈利能力方面面临困难。净利润率为 <strong>9.67%</strong>，公司可能在有效控制成本方面遇到挑战。</p>
</div><p><strong>Return on Equity (ROE):</strong> Teva Pharmaceutical Indus's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>6.15%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<div class="lb-trans"><p><strong>股本回报率（ROE）：</strong> Teva Pharmaceutical Indus 的 ROE 表现突出，超过行业平均水平。ROE 为 <strong>6.15%</strong>，表明公司有效利用股本并展现出强劲的财务表现。</p>
</div><p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>1.08%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<div class="lb-trans"><p><strong>资产回报率（ROA）：</strong> 该公司的 ROA 低于行业基准，表明在有效利用资产方面可能存在困难。ROA 为 <strong>1.08%</strong>，公司可能需要解决从资产中产生令人满意的回报的挑战。</p>
</div><p><strong>Debt Management:</strong> Teva Pharmaceutical Indus's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>2.35</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<div class="lb-trans"><p><strong>债务管理：</strong> 梯瓦制药的债务与股本比率显著高于行业平均水平，达到 <strong>2.35</strong>。这表明其对借款资金的依赖程度较高，令人对财务杠杆产生担忧。</p>
</div><h2>Understanding the Relevance of Analyst Ratings</h2>
<div class="lb-trans"><h2>理解分析师评级的相关性</h2>
</div><p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.</p>
<div class="lb-trans"><p>分析师是银行和金融系统中的专家，通常针对特定股票或特定行业进行报告。这些人研究公司的财务报表，参加电话会议和会议，并与相关内部人士交谈，以确定股票的分析师评级。通常，分析师每季度会对每只股票进行评级。</p>
</div><p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<div class="lb-trans"><p>除了标准评估外，一些分析师还会对增长预期、收益和收入等指标进行预测，为投资者提供额外的指导。使用分析师评级的用户应注意，这些专业建议受到人类观点的影响，可能会存在变动。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自动内容引擎生成，并经过编辑审核。</p>
</div>

11 位分析师对梯瓦制药的评估：你需要了解的内容